Coherus Biosciences | CHRS - Cost Of Sales


Coherus Biosciences reported $4.04M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.6B 187M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Fujifilm JPY 550.58B 40.74B Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Merck USD 2.94B 380M Mar/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xencor USD 61.66M 50.95M Jun/2025
Zoetis USD 672M 71M Mar/2026